Meeder Asset Management Inc Otonomy, Inc. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $2.24 $1,206 - $10,808	4,825 Added 173.94%	7,599 $2,000
Q1 2022 May 10, 2022	BUY	$1.72 - $2.47 $4,771 - $6,851	2,774 New	2,774 $7,000
Q4 2021 Feb 11, 2022	SELL	$1.69 - $2.31 $4,688 - $6,407	-2,774 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$2.49 - $6.23 $6,907 - $17,282	2,774 New	2,774 $7,000
Q4 2020 Feb 09, 2021	SELL	$3.48 - $6.47 $9,653 - $17,947	-2,774 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.58 - $4.06 $5,299 - $13,617	-3,354 Reduced 54.73%	2,774 $5,000
Q4 2019 Feb 13, 2020	SELL	$2.13 - $3.83 $943 - $1,696	-443 Reduced 6.74%	6,128 $23,000
Q3 2019 Oct 17, 2019	BUY	$2.12 - $2.86 $1,452 - $1,959	685 Added 11.64%	6,571 $16,000
Q4 2018 Jan 17, 2019	BUY	$1.51 - $2.93 $3,954 - $7,673	2,619 Added 80.17%	5,886 $11,000
Q3 2018 Nov 02, 2018	BUY	$2.6 - $3.95 $7,477 - $11,360	2,876 Added 735.55%	3,267 $0
Q1 2018 May 03, 2018	SELL	$4.05 - $6.1 $1,478 - $2,226	-365 Reduced 48.28%	391 $2,000
Q4 2017 Feb 02, 2018	SELL	$2.8 - $5.55 $686 - $1,359	-245 Reduced 24.48%	756 $4,000
Q3 2017 Oct 20, 2017	BUY	$3.2 - $20.8 $3,203 - $20,820	1,001	1,001 $3,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.